alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with nalorphine in 1 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (nalorphine) | Trials (nalorphine) | Recent Studies (post-2010) (nalorphine) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 1,134 | 41 | 6 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | nalorphine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.1095 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.004 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.1095 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.004 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.004 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.1095 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, BG; Kimes, AS; London, ED; Scheffel, U; Wilson, AA | 1 |
1 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and nalorphine
| Article | Year |
|---|---|
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
Topics: Animals; Autoradiography; Binding Sites; Binding, Competitive; Brain; Guanidines; Guinea Pigs; Iodobenzenes; Male; Mice; Receptors, sigma; Tissue Distribution | 1992 |